TAE Life Sciences and CNAO Announce a Research and Clinical Collaboration for the Implementation of a New Facility with Boron Neutron Capture Therapy System in Italy

October 27, 2020

TAE Life Sciences, a biologically-targeted radiation therapy company developing a breakthrough, accelerator-based boron neutron capture therapy (BNCT) system, today announced that it has entered into an agreement with National Center of Oncological Hadrontherapy (CNAO) to provide its Alphabeam™ Neutron System for the treatment of invasive, recurrent and difficult to treat cancers.

TAE Life Sciences notes BNCT research has demonstrated compelling results for some of the most difficult to treat cancers, including recurrent head and neck, glioblastomas and melanoma. This technique looks promising in treating cancer patients for whom other treatment options have been exhausted or unavailable.

“Our partnership with renowned CNAO underscores the growing momentum for the adoption of BNCT as a cancer therapy that delivers more precise targeted radiation to cancer cells while sparing surrounding healthy tissue,” said Bruce Bauer, Chief Executive Officer of TAE Life Sciences. “Our novel targeted boron-10 drugs that are in development and proprietary state-of-the-art accelerator-based neutron source have the potential to make BNCT a new pillar in cancer therapy and working with CNAO, a leading world cancer center, will enable us to further our goal of truly changing the landscape of cancer treatment.”

TAE Life Sciences patented neutron source has been specifically designed for clinical BNCT use in a hospital facility and produces low-energy neutrons that neutralize tumors containing accumulated boron-10, a non-toxic, non-radioactive isotope that when administered to a patient selectively collects in cancer cells. Because the boron-10 carrier drug is highly targeted to cancer cells, a patient can be treated in just one or two treatment sessions, without many of the side effects of traditional radiation therapy.

“The addition of the Alphabeam System is integral to our plans to expand our therapeutic reach and will enable us to conduct clinical BNCT research for the treatment of head and neck cancers, brain cancers like glioblastomas and malignant melanomas,” said Prof. Gianluca Vago, President of CNAO.

“The Alphabeam System will be installed alongside a new proton system to provide complimentary radiation therapy treatment. With the implementation of this new technology, and the collaboration of many institutions, like INFN and the University of Pavia among others, CNAO will be the unique facility able to combine treatments with protons, heavy ions (carbon ions and other species), and neutrons for BNCT. This partnership supports our vision of a multidisciplinary approach towards customized cancer therapy to benefit patients.”


Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Thermo Scientific™ Dionex™ Inuvion™ Ion Chromatography (IC) system, helping to make ion analysis simpler and more intuitive for labs of all sizes. The new analytical instrument is designed to be easily reconfigurable, providing those who require determination of ionic and small polar compounds with a one stop shop for consistent, reliable ion analysis.
This new collaboration is another example of Blacksmith's creative deal-making with top tier partners that bring expertise to the table which helps de-risk and accelerate scientific discoveries for the development of valuable products.
Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection 1,000 mL (2 units/mL), is indicated as an anticoagulant to maintain catheter patency.
Through this agreement, RaySearch acquires full ownership of all rights to the product DrugLog for its application in the field of oncology, including the measuring device, calibration parameters, source code, as well as intellectual property rights.
Anna Kazanchyan, MD, Founder and CEO of Saghmos Therapeutics. "We are very pleased to announce the Notice of Allowance for our second patent, which will enhance the long-term value of ST-62516. Saghmos continues to build its intellectual property estate."

By using this website you agree to accept Medical Device News Magazine Privacy Policy